Neotherapuetics possibly has a breakthrough drug - NEOT Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT

NEOT 1.919

+4.3%

Jan 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (201)	8/5/2003 2:22:32 AM
From: Icebrg	Read Replies (2) of 204

GPC Biotech Q2 report [In their Q2 report GPC Biotech continues to sound optimistic with regard to the prospects of Satraplatin. They have been pushing very aggressively for the drug for quite some time now. Too hard? Only time will tell. But I am normally more comfortable with companies that gets the approval before they publicly start to dream about future market shares.] The Company also announced that it has recently performed a more comprehensive market analysis, which indicates that -- with the help of a pharmaceutical partner -- the market potential of satraplatin could be more than $500 million in annual peak sales. In addition to the market in hormone- refractory prostate cancer, this analysis includes modest penetration assumptions in other areas of potential application for satraplatin: in earlier stages of prostate cancer; in other tumor types where satraplatin has demonstrated clinical activity, such as small-cell lung cancer and ovarian cancer; and in combination with radiotherapy, an application where the oral activity of satraplatin would be of particular advantage. Bernd R. Seizinger, M.D., Ph.D., President and Chief Executive Officer, said, "GPC Biotech has had important achievements in both drug development and discovery technologies in the year to date. Positive late-stage clinical data on the efficacy of satraplatin in hormone-refractory prostate cancer were presented at ASCO, the major cancer-related medical event of the year. We remain on track to begin our Phase 3 registrational trial for satraplatin this quarter. Additionally, as we are planning to partner satraplatin prior to marketing approval, we have recently undertaken a more comprehensive market analysis of the compound's sales potential. That analysis indicates that, with the aid of a pharmaceutical partner, the market potential of satraplatin could be more than $500 million in annual peak sales. We look forward to continued progress in both our oncology drug development and technology efforts in the months ahead."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next